INTRODUCTION AND OBJECTIVES: Adjuvant chemotherapy (AC) is recommended in patients with pT3-4 and/or pN1-3 bladder cancer after radical cystectomy (RC). However, its benefit on survival outcomes is still controversial. The aims of this study were: to discover whether AC may improve survival in these patients; to identify the most effective AC regimens and any predictors of CSS and OS. METHODS: We identified 996 patients with pT3-4 and/or pN1-3 disease at RC performed at a tertiary referral center between 1998-2017. Exclusion criteria were: incomplete data; non-urothelial histology at RC. Patients were grouped as follow: 1) optimal AC (OAC): cisplatin-based AC for >3 cycles; 2) suboptimal AC (SAC): cisplatin-based AC for <3 cycles or non cisplatin-based AC; 3) no AC. Propensity score matching by age, sex, neoadjuvant chemotherapy, pT, pN, eGFR and post-operative ECOG selected 92, 53 and 104 patients respectively. Descriptive statistics were used to show baseline data. Kaplan-Meyer curves and log-rank tests were used to compare CSS and OS between AC regimens. Multivariable Cox regression analysis was used to identify any predictors of CSS and OS.
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RESULTS: Matching variables were balanced between groups, except for positive pN status (OAC vs SAC vs CONCLUSIONS: Despite the poor prognosis associated to pT3-4 and/or pN1-3 disease, OAC may improve survival outcomes after RC in selected fit patients, though it may not affect progression.
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MP38-20 COMBINED REPORTING OF SURGICAL QUALITY, CANCER CONTROL AND FUNCTIONAL OUTCOMES OF ROBOT-ASSISTED RADICAL CYSTECTOMY WITH ORTHOTOPIC NEOBLADDER: THE TRIFECTA ACHIEVEMENT
Aldo Brassetti*, Gabriele Tuderti, Salvatore Guaglianone, Maria Consiglia Ferriero, Umberto Anceschi, Francesco Minisola, Riccardo Mastroianni, Rocco Simone Flammia, Michele Gallucci, Giuseppe Simone, Rome, Italy INTRODUCTION AND OBJECTIVES: Robot-assisted radical cystectomy (RARC) with orthotopic neobladder (ON) is associated with heterogeneous surgical, functional and oncological outcomes. These are currently presented separately, while the success of this surgery depends on a combination of good cancer control, no surgery-related complications and urinary continence. We propose a combination of three standardized and reproducible postoperative criteria (Trifecta) to optimize outcomes reporting after RARC with ON.
METHODS: our prospectively maintained database of patients undergoing RARC with intracorporeal ON for bladder cancer (BC) was queried for baseline demographics, clinical, pathologic and peri-/postoperative data. We defined the "trifecta" as the combination of daily urinary continence, no reoperations (meaning neither post-operative complications Clavien-Dindo ! 3 nor other surgical interventions related to RARC/ON, after discharge) and recurrence-free status, all assessed at one year. Kaplan-Meier analysis was performed to assess the predictive role of trifecta outcomes on overall survival. Univariable and multivariable logistic regression analyses were performed to identify predictors of trifecta achievement. RESULTS: Overall, 137 patients were included in the analysis (Table 1) ; 72 (53%) achieved the trifecta (Figure 1 ). On Kaplan-Meier analysis, it was significantly associated with a better overall survival (OS) (Log Rank [ 0.032). On univariable analysis, age, body mass index, neoadjuvant chemotherapy and pathological stage predicted trifecta; on multivariable regression, this association was only confirmed for age and stage (Table 2) .
